IRIS
LAZZARIN, ADRIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.733
EU - Europa 1.695
NA - Nord America 994
SA - Sud America 247
AF - Africa 16
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 1
Totale 4.691
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 978
SE - Svezia 715
SG - Singapore 640
HK - Hong Kong 539
CN - Cina 477
RO - Romania 266
IT - Italia 243
BR - Brasile 228
RU - Federazione Russa 197
DE - Germania 117
FI - Finlandia 62
IN - India 27
AT - Austria 22
IE - Irlanda 18
NL - Olanda 18
TR - Turchia 10
CA - Canada 9
AR - Argentina 8
PK - Pakistan 8
GB - Regno Unito 7
BE - Belgio 5
EU - Europa 5
MA - Marocco 5
MD - Moldavia 5
ZA - Sudafrica 5
BD - Bangladesh 4
CZ - Repubblica Ceca 4
MX - Messico 4
TN - Tunisia 4
UA - Ucraina 4
CO - Colombia 3
IR - Iran 3
JP - Giappone 3
LT - Lituania 3
TH - Thailandia 3
UZ - Uzbekistan 3
BO - Bolivia 2
CL - Cile 2
EC - Ecuador 2
FR - Francia 2
GE - Georgia 2
ID - Indonesia 2
JO - Giordania 2
OM - Oman 2
PS - Palestinian Territory 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AU - Australia 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ES - Italia 1
GT - Guatemala 1
HU - Ungheria 1
IL - Israele 1
IQ - Iraq 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LV - Lettonia 1
PA - Panama 1
PE - Perù 1
PT - Portogallo 1
RS - Serbia 1
VE - Venezuela 1
Totale 4.691
Salva come PNG Salva come JPEG
Città #
Hong Kong 536
Shanghai 263
Lawrence 219
Princeton 219
Singapore 200
Milan 107
Moscow 104
Ashburn 87
New York 75
Helsinki 52
Nuremberg 43
Boardman 38
Guangzhou 22
Pune 22
Rome 21
Washington 17
Dublin 15
São Paulo 15
Beijing 13
Los Angeles 10
Reston 10
Shenzhen 10
Belo Horizonte 9
Cesano Boscone 8
Seattle 8
The Dalles 8
Vienna 8
Kassel 7
Dallas 6
Quanzhou 6
Chisinau 5
Curitiba 5
Falkenstein 5
Wuyuan 5
Betim 4
Borås 4
Hamilton 4
Ortezzano 4
Porto Alegre 4
Rio de Janeiro 4
Rutigliano 4
St Petersburg 4
Turku 4
West Jordan 4
Wuxi 4
Angera 3
Ballincollig 3
Bauru 3
Belém 3
Brussels 3
Campinas 3
Espoo 3
Feira de Santana 3
Istanbul 3
Karachi 3
Lappeenranta 3
Mexico City 3
Padova 3
Romagnano Sesia 3
Santa Clara 3
Santo André 3
Tashkent 3
Tokyo 3
Toronto 3
Xi'an 3
Amman 2
Amsterdam 2
Bangkok 2
Barreiras 2
Belford Roxo 2
Brasília 2
Campina Grande 2
Campos do Jordão 2
Caruaru 2
Concórdia 2
Concórdia do Pará 2
Cuiabá 2
Dalian 2
Dnipro 2
Dongyang 2
Duchcov 2
Durban 2
Florence 2
Ghent 2
Glenwood 2
Goiânia 2
Guarulhos 2
Hangzhou 2
Hanover 2
Hyderabad 2
Johannesburg 2
London 2
Manassas 2
Mauá 2
Medellín 2
Montes Claros 2
Munich 2
Muscat 2
Nova Iguaçu 2
Panchkula 2
Totale 2.352
Salva come PNG Salva come JPEG
Nome #
The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients 333
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 90
Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients with Advanced Liver Disease during Anti-HCV Treatment with Direct-Acting Antiviral Regimens Including Ribavirin 62
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 58
HLA-associated susceptibility to AIDS: HLA B35 is a major risk factor for Italian HIV-infected intravenous drug addicts 49
Biobanking for COVID-19 research 48
Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls 48
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy 45
A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients 38
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study) 35
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 35
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 34
VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression 34
Circulating cathodic antigen (CCA) urine rapid test for diagnosis of Schistosoma mansoni infestation: preliminary data of a cohort study of Egyptian patients coming from an endemic area 33
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 32
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 31
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients 31
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection 31
Immunological status in heroin addicts: effects of methadone maintenance treatment 30
Evolution of the E2 region of hepatitis C virus in an infant infected by mother-to-infant transmission 30
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 30
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic 30
Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption 29
Impact of HAART on liver histology of HIV/HCV coinfected patients 28
Cerebrospinal fluid beta 2-microglobulin in AIDS related central nervous system involvement. 28
Early diagnosis of HIV infection in infants 28
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 28
Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. 28
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 28
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 27
Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals 27
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 27
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 27
ABC of AIDS: Treatment of infections and antiviral agents 27
A study of cellular immunity in newborns after prevention of respiratory distress syndrome (RDS). 26
Naive HIV/HCV-coinfected patients have higher intrahepatic pro-inflammatory cytokines than coinfected patients treated with antiretroviral therapy 26
Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy 26
Therapeutic trials with HPA23, alpha-IFN and ribavirin in AIDS patients 26
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 26
Bictegravir 26
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011 26
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 25
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 25
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 25
Western blot in treated people with HIV-1 chronic infection: frequency of negative HIV-1 pol genes 25
GB Virus C and Survival in Persons with HIV Infection 24
Morphogenesis, evolution and prognostic significance of lymphatic tissue lesions in HIV infection 24
Darunavir for the treatment of HIV infection 24
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 24
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 24
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 24
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 24
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 23
Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor-Based Combination Antiretroviral Therapy: The D:A:D Study 23
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 23
Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. 23
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 23
Dynamics of the M184V mutation by allele-specific PCR (AS-PCR) in patients receiving lamivudine or emtricitabine monotherapy or undergoing treatment interruption (TI) 23
Carotid vessels lesions in experienced HIV-1-infected subjects affected or not by hypertension and/or diabetes mellitus 23
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents 23
Risk of HIV-related diseases in heterosexuals importing infection from Zaire 22
Cytomegalovirus pneumonia in AIDS patients: value of cytomegalovirus culture from BAL fluid and correlation with lung disease 22
Evaluation of the detection of human papillomavirus genotypes in cervical specimens by hybrid capture as screening for precancerous lesions in HIV-positive women 22
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection 22
Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients 22
Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients 22
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study 22
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015 22
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus 22
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression 22
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males 22
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort 22
Evolving treatment implementation among HIV- infected pregnant women and their partners: Results from a national surveillance study in Italy, 2001-2015 22
Evaluation of total HIV-DNA changes in HIV-1 infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-One Study 22
Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin 21
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients 21
Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors 21
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 21
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients 21
Cytomegalovirus infection of the central nervous system in patients with aids: Diagnosis by DNA amplification from cerebrospinal fluid 21
Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy 21
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 21
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 21
Point-of-care testing for hepatitis C virus infection at an Italian dental clinic: portrait of the pilot study population 21
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: A sub-study of the NEAT001/ANRS143 randomized trial 21
Analysis of impediments to the maintenance in care of people with HIV in Italy 21
HEFFICON: HIV Effectiveness Italian Conference 21
HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe 21
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 21
Early Diagnosis and Linkage to Care: an Experience over 14 years of Point of Care Rapid HIV Testing 20
Epidemiological aspects of human immunodeficiency virus infection in Milan. 20
Experiences with immunomodulant agents in HIV infections 20
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response 20
Long-lasting CCR5 internalization by antibodies in a subset of long-term non progressors: a possible protective effect against disease progression 20
Evaluation of contrast-enhancing brain lesions in AIDS patients by means of Epstein-Barr virus detection in cerebrospinal fluid and 201thallium single photon emission tomography 20
Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman 20
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism 20
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 20
Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: Maraviroc, raltegravir, etravirine 20
LONG-TERM SURVIVAL AMONG HIV-1 INFECTED PATIENTS WITH AIDS AND NON AIDS RELATED MALIGNANCIES 20
Totale 2.996
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.909
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.909
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201 0 0 0 0 0 0 0 0 0 0 0 1
2020/202191 0 0 1 6 0 14 11 57 1 0 1 0
2021/2022145 0 0 0 77 6 8 8 13 10 7 3 13
2022/20231.203 483 292 102 7 10 125 33 85 48 1 11 6
2023/2024605 7 29 81 49 45 137 13 68 0 15 80 81
2024/20252.707 375 58 37 82 83 257 714 234 487 361 19 0
Totale 4.955